Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Xiaomi Shares Jump on Europe EV Expansion Plan 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
PHOENIX, Feb. 23, 2018 -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its fourth quarter and full year 2017 financial results on Thursday, March 8, after the U.S. financial markets close.
Following the release, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conference call at 5:00 p.m. Eastern Standard Time to discuss the results.
Interested parties can listen to the call live via the company’s website, https://www.insysrx.com/, on the Investors section Presentations & Events page; or by dialing 844-263-8304 (from inside the U.S.) or 213-358-0958 (from outside the U.S.). A webcasted replay of the call will be available on the site a few hours after the event.
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, the company is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.
| CONTACT: | Corporate Communications | Investor Relations |
| Joe McGrath | Jackie Marcus or Chris Hodges | |
| INSYS Therapeutics | Alpha IR Group | |
| 480-500-3101 | 312-445-2870 | |
| [email protected] | [email protected] |
